There are currently 1544 people in the U.S. waiting for a lung transplant [1]. Every year many people die while on the waiting list. A major problem preventing more lung transplants from occurring is the lack of ability to properly assess the lungs prior to transplant. It is estimated that 70–80% of organ donors' lungs are not used due to too many unknowns as to how the graft may perform post-transplant [2].

One approach that has been proposed to help fill this unmet need is employing ex vivo lung perfusion. There are currently three devices that have been developed for this specific purpose: Transmedics organ care system (OCS), Vivoline, and XVIVO. All the three devices have been approved for use in Europe: only the XVIVO has FDA approval. These units all provide one with the ability to assess the relative function...

References

References
1.
UNOS
, “
Transplant Trends
,” United Network for Organ Sharing, Richmond, VA, accessed Nov. 6, 2015, https://www.unos.org/data/transplant-trends/#waitlists_by_organ
2.
Coll
,
E.
,
Santos
,
F.
,
Ussetti
,
P.
,
Canela
,
M.
,
Borro
,
J.
,
De La Torre
,
M.
,
Varela
,
A.
,
Zurbano
,
F.
,
Mons
,
R.
,
Morales
,
P.
,
Pastor
,
J.
,
Salvatierra
,
A.
,
de Pablo
,
A.
,
Gamez
,
P.
,
Moreno
,
A.
,
Sole
,
J.
, and
Roman
,
A.
,
2013
, “
The Spanish Lung Transplant Registry: First Report of Results (2006–2010)
,”
Arch. Bronconeumol.
(English edition),
49
(
2
), pp.
70
78
.
You do not currently have access to this content.